Masimo (NASDAQ:MASI) Updates FY 2025 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.620-5.790 for the period, compared to the consensus earnings per share estimate of 5.320. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Masimo Price Performance

Shares of MASI traded down $1.09 during mid-day trading on Thursday, hitting $141.06. The company’s stock had a trading volume of 218,881 shares, compared to its average volume of 647,158. The firm has a 50-day moving average price of $144.91 and a 200 day moving average price of $153.96. The stock has a market capitalization of $7.66 billion, a price-to-earnings ratio of -16.56 and a beta of 1.28. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61. Masimo has a fifty-two week low of $133.70 and a fifty-two week high of $194.88.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. The company had revenue of $617.00 million for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. On average, research analysts predict that Masimo will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MASI has been the subject of several research reports. Wall Street Zen upgraded shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Zacks Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. BTIG Research reiterated a “buy” rating and issued a $198.00 target price on shares of Masimo in a research note on Wednesday. Piper Sandler lifted their target price on shares of Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Finally, Wells Fargo & Company reduced their price objective on shares of Masimo from $190.00 to $187.00 and set an “overweight” rating for the company in a research note on Wednesday. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Masimo currently has an average rating of “Moderate Buy” and an average price target of $194.00.

Insider Activity

In other news, Director William R. Jellison bought 3,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were acquired at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the acquisition, the director owned 4,790 shares in the company, valued at approximately $699,244.20. This represents a 167.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 16.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Masimo

Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Masimo during the second quarter worth $86,000. Dynamic Technology Lab Private Ltd acquired a new position in Masimo during the first quarter worth $220,000. Tower Research Capital LLC TRC increased its holdings in shares of Masimo by 12.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,516 shares of the medical equipment provider’s stock valued at $255,000 after purchasing an additional 166 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of Masimo in the second quarter valued at $356,000. Finally, Jones Financial Companies Lllp increased its holdings in shares of Masimo by 1,267.1% in the first quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock valued at $367,000 after purchasing an additional 2,040 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.